BioLife Solutions (BLFS) Stock Forecast & Price Target

BioLife Solutions is supported by improving fundamentals, with 2Q26 revenue of $28.5 million, up 21% year over year, and adjusted operating income of $3.1 million versus a loss in 2Q25, showing meaningful profitability leverage in the core business. The outlook is further strengthened by expected 3Q26E revenue of $29.5 million and full-year 2026E revenue of $74.7 million, reflecting 21% growth, as the company benefits from a refocused portfolio centered on higher-margin cell processing and CryoStor. The pending acquisition by Repligen adds strategic validation, and management cited at least $20 million of year-one synergies and at least 5 cents of year-one EPS accretion, reinforcing confidence in BioLife’s underlying asset quality and growth trajectory.

BioLife Solutions is facing a cautious outlook because its fundamentals show only modest operating improvement despite a still-narrow business mix, with Cell Processing and CryoStor driving most revenue and gross margin slipping to 64% from 65% in the second quarter. Although biopreservation media is used in about 250 U.S. clinical trials, including over 30 Phase 3 trials, the company remains exposed to regulatory risk, competition from larger players, and lack of profitability, which can limit durable standalone upside. Its $113.1 million in cash and equivalents and $7.4 million in adjusted EBITDA provide some cushion, but the pending Repligen acquisition and expected close in 4Q26 suggest the investment case is more event-driven than rooted in long-term independent growth.